Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Martin Vanden Eede: Can We Safely Reduce Anticoagulation During ECMO?
Martin Vanden Eede/ LinkedIn
Jul 9, 2026, 18:21

Martin Vanden Eede: Can We Safely Reduce Anticoagulation During ECMO?

Martin Vanden Eede, Cardiologist and Intensive Care Physician at ZAS, shared a post on LinkedIn about a recent article by Olivier van Minnen et al. published in The Lancet, adding:

“Can we safely reduce anticoagulation during ECMO?

An interesting Multicentre randomized controlled non-inferiority trial compared:

  1. Standard-dose UFH (current standard of care)
  2. Low-dose UFH
  3. Therapeutic low-molecular-weight heparin (LMWH)

The hypothesis was straight forward: Less anticoagulation may reduce bleeding without increasing thrombosis.

The primary endpoint was a composite of:

  • Severe bleeding during ECMO
  • Severe thromboembolic complications
  • All-cause mortality at 6 months

This endpoint reflects the real clinical balance between preventing thrombosis and avoiding bleeding.

Primary endpoint:

  • Standard UFH 81%
  • Low-dose UFH 72%
  • LMWH 75%

Both low-dose UFH and LMWH met the predefined criterion for non-inferiority, meaning they were not worse than standard-dose UFH regarding the combined endpoint.

Equally important was that:

  • Reduced-intensity strategies consistently showed fewer bleeding events.
  • Lowering anticoagulation did not increase thrombotic complications.
  • Similar transfusion requirements between groups
  • Fewer oxygenator exchanges with LMWH
  • Low-dose UFH showed the highest probability of being cost-effective.

These findings are likely to influence future ECMO anticoagulation guidelines and support a shift toward lower-intensity anticoagulation in appropriately selected patients.

Three Key Points

  1. Lower-intensity anticoagulation (low-dose UFH or therapeutic LMWH) was non-inferior to standard-dose UFH during ECMO.
  2. Reducing anticoagulation did not increase thrombotic complications and showed a consistent trend toward fewer severe bleeding events.
  3. The study provides strong evidence that routine ECMO anticoagulation targets should be reconsidered, potentially making lower-intensity anticoagulation the future standard of care.”

Titile: Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial

Authors: Olivier van Minnen, Annemieke Oude Lansink-Hartgring, Rombout B. E. van Amstel, Bas van den Bogaard, Jeroen J. H. Bunge, Thijs S. R. Delnoij, Joep M. Droogh, Laurien van Koppenhagen, Carlos V. Elzo Kraemer, Marijn Kuijpers, Jacinta J. Maas, Jesse de Metz, Marcel C. G. van de Poll, S. Jorinde Raasveld, Dinis dos Reis Miranda, Priya Vart, Karin M. Vermeulen, Alexander P. J. Vlaar, Walter M. van den Bergh, Maite M. T. van Haeren, Matty Koopmans, Marcella C. A. Müller, Dirk W. Donker, Christiaan L. Meuwese, Sakir Akin

Martin Vanden Eede: Can We Safely Reduce Anticoagulation During ECMO?

Stay updated on all scientific advances with Hemostasis Today.

Alexander P. J. Vlaar Annemieke Oude Lansink-Hartgring Anticoagulation Bas van den Bogaard Carlos V. Elzo Kraemer Christiaan L. Meuwese Dinis dos Reis Miranda Dirk W. Donker ECMO Health Hematology Hemostasis Hemostasis News Hemostasis Today Jacinta J. Maas Jeroen J. H. Bunge Jesse de Metz Joep M. Droogh Karin M. Vermeulen Laurien van Koppenhagen LMWH Maite M. T. van Haeren Marcel C. G. van de Poll Marcella C. A. Müller Marijn Kuijpers Martin Vanden Eede Matty Koopmans Medicine Olivier van Minnen Priya Vart Rombout B. E. van Amstel S. Jorinde Raasveld Sakir Akin Thijs S. R. Delnoij UFH Walter M. van den Bergh
NewsFeed